Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
暂无分享,去创建一个
Doriano Fabbro | D. Fabbro | B. Monia | T. Geiger | Brett P. Monia | Joseph F. Johnston | Thomas Geiger | Marcel Muller | J. Johnston | M. Muller | Brett P. Monia
[1] K. Blumer,et al. Diversity in function and regulation of MAP kinase pathways. , 1994, Trends in biochemical sciences.
[2] T. Sugimura,et al. Molecular cloning of an activated human oncogene, homologous to v-raf, from primary stomach cancer. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[3] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.
[4] J. Groffen,et al. Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras oncogene. , 1986, Nucleic acids research.
[5] O. Uhlenbeck. Complementary oligonucleotide binding to transfer RNA. , 1972, Journal of molecular biology.
[6] M. Olivé,et al. Breast tumor cell lines from pleural effusions. , 1974, Journal of the National Cancer Institute.
[7] T. Yamamoto,et al. Detection of a raf-related and two other transforming DNA sequences in human tumors maintained in nude mice. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[8] A. Porras,et al. Dissociation between activation of Raf-1 kinase and the 42-kDa mitogen-activated protein kinase/90-kDa S6 kinase (MAPK/RSK) cascade in the insulin/Ras pathway of adipocytic differentiation of 3T3 L1 cells. , 1994, The Journal of biological chemistry.
[9] P. D. Cook,et al. Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. , 1993, The Journal of biological chemistry.
[10] D. Fabbro,et al. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti‐proliferative as well as In vivo anti‐tumor activity , 1989, International journal of cancer.
[11] E. Wickstrom,et al. Walking along human c-myc mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5' cap region. , 1991, Oncogene research.
[12] C. Bennett,et al. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. , 1992, Molecular pharmacology.
[13] Jonathan A. Cooper,et al. Mammalian Ras interacts directly with the serine/threonine kinase raf , 1993, Cell.
[14] C. Bennett,et al. Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. , 1994, Journal of immunology.
[15] S. Crooke,et al. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. , 1995, The Journal of pharmacology and experimental therapeutics.
[16] K. Stecker,et al. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. , 1997, The Journal of pharmacology and experimental therapeutics.
[17] V. Stanton,et al. Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences , 1987, Molecular and cellular biology.
[18] R. Weinberg,et al. Isolation of a transforming sequence from a human bladder carcinoma cell line , 1982, Cell.
[19] J. Bos,et al. The ras gene family and human carcinogenesis. , 1988, Mutation research.
[20] Jonathan A. Cooper,et al. A single amino acid change in Raf-1 inhibits Ras binding and alters Raf-1 function. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[21] T. Cech,et al. Catalysis of RNA cleavage by the Tetrahymena thermophila ribozyme. 2. Kinetic description of the reaction of an RNA substrate that forms a mismatch at the active site. , 1990, Biochemistry.
[22] J. Troppmair,et al. The ins and outs of Raf kinases. , 1994, Trends in biochemical sciences.
[23] S. Crooke. Therapeutic applications of oligonucleotides. , 1992, Bio/technology.
[24] G. Condorelli,et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo , 1995, Nature Medicine.
[25] E. Nishida,et al. The MAP kinase cascade is essential for diverse signal transduction pathways. , 1993, Trends in biochemical sciences.
[26] J. Cleveland,et al. Oncogenes: clinical relevance. , 1987, Haematology and blood transfusion.
[27] D. Ecker,et al. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. , 1992, The Journal of biological chemistry.
[28] T. Tokunaga,et al. Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence of AACGTT to Murine Splenocytes Enhances Interferon Production and Natural Killer Activity , 1994, Microbiology and immunology.
[29] P. Warne,et al. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro , 1993, Nature.
[30] R. Wagner. The state of the art in antisense research , 1995, Nature Genetics.
[31] T. Pawson,et al. Mutational activation of c-raf-1 and definition of the minimal transforming sequence , 1990, Molecular and cellular biology.
[32] N. Dean,et al. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[33] S. Elledge,et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1 , 1993, Nature.
[34] D. Ecker,et al. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. , 1991, Nucleic acids research.
[35] S. Freier,et al. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. , 1991, The Journal of biological chemistry.
[36] C. Stein,et al. Does antisense exist? , 1995, Nature Medicine.
[37] J. Ulmer,et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.
[38] Osamu Yano,et al. Oligonucleotide Sequences Required for Natural Killer Cell Activation , 1992, Japanese journal of cancer research : Gann.
[39] D. Ecker,et al. Implication of RNA structure on antisense oligonucleotide hybridization kinetics. , 1992, Biochemistry.
[40] R. Griffey,et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. , 1996, The Journal of pharmacology and experimental therapeutics.
[41] F H Reynolds,et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[42] S. Freier,et al. The binding of complementary oligoribonucleotides to yeast initiator Transfer RNA. , 1975, Biochemistry.
[43] E. Reddy,et al. Nucleotide sequence analysis of the T24 human bladder carcinoma oncogene. , 1983, Science.
[44] E. Kuramoto,et al. DNA from Bacteria, but Not from Vertebrates, Induces Interferons, Activates Natural Killer Cells and Inhibits Tumor Growth , 1992, Microbiology and immunology.
[45] T. Pawson,et al. Role of raf oncogenes in lung carcinogenesis , 1988 .